Search

everythinglearnresearchcommunity

for

Search:↓

Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

NXC736 significantly reduced hair loss in mice with alopecia areata.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

LGD1069 effectively prevents breast tumors in mice without toxicity.

New compounds were made that are promising for prostate cancer therapy.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.

Naringenin and its combination with minoxidil significantly improved hair growth in mice.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Minoxidil prevents serotonin loss from MDMA by affecting potassium channels and increasing Akt phosphorylation.

MR antagonists may improve skin health and wound healing, especially in aging.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.

Agouti protein affects melanocortin receptors through competitive antagonism and receptor down-regulation.

Allopregnanolone may help prevent nicotine withdrawal symptoms.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Early changes in brain chemicals affect how a drug reduces alcohol intake in rats.

The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.

DHA-NLC may improve drug delivery and reduce side effects for cancer treatment.

SARMs work differently in tissues due to unique interactions and structures.